An investigation for investors in NASDAQ:EGRX shares over potential securities laws violations by Woodcliff Lake, NJ based Eagle Pharmaceuticals Inc (NASDAQ:EGRX and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) concerning whether a series of statements by Eagle Pharmaceuticals Inc (NASDAQ:EGRX regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On February 25, 2016, Eagle Pharmaceuticals’ CEO stated, regarding the pending New Drug Application (“NDA”) for the Company’s anticoagulant drug KANGIO™, “We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.”
Then, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA “cannot approve the application in its present form and requested additional information” regarding the substances used in KANGIO™.
Shares of specialty pharmaceutical company Eagle Pharmaceuticals Inc (NASDAQ:EGRX) declined to as low as $35.10 per share on March 28, 2016.
On May 27, 2016, NASDAQ:EGRX shares closed at $46.73 per share.
Those who purchased NASDAQ:EGRX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego